MEMPHIS, TN, USA I April 30, 2013 I GTx, Inc. (GTXI), announced today that it is initiating a proof of concept, Phase 2, open-label clinical study to evaluate enobosarm (GTx-024), a selective androgen receptor modulator (SARM), for the potential treatment of metastatic breast cancer.
“We know from prior studies that women with hormone receptor positive metastatic breast cancer which has progressed following treatment with tamoxifen often respond to androgen (male hormone) therapy; yet the side effects, such as facial hair growth and deepening of the voice, are not acceptable to most patients,” said Beth A. Overmoyer, M.D., a clinical investigator in this enobosarm Phase 2 study and the Director, Inflammatory Breast Cancer Program, Dana Farber Cancer Institute and Assistant Professor of Medicine at the Harvard Medical School. “Hopefully, treatment with enobosarm will result in efficacy similar to androgen therapy without the masculinizing side effects.”
“We believe enobosarm has the potential to selectively treat metastatic breast cancer while minimizing the unwanted side effects associated with steroidal androgens,” said Mitchell S. Steiner, MD, Chief Executive Officer of GTx. “Enobosarm would be the first new targeted hormonal therapy introduced for the treatment of breast cancer in many years.”
The proof of concept, Phase 2, open-label study will randomize twenty (20) postmenopausal women with estrogen receptor (ER) positive metastatic breast cancer who have previously responded to hormone therapy at approximately six clinical sites in the United States. The women will receive 9 mg of enobosarm once a day until they evidence clinical progression or have completed 336 days of treatment. The primary endpoint is clinical benefit, which will be assessed at 6 months, and is defined as either those women receiving treatment who have demonstrated a complete response (disappearance of all targeted lesions), a partial response (at least a 30% decrease in the sum of the diameters of the targeted lesions) or stable disease (no disease progression from baseline). The response from treatment will be correlated with androgen receptor (AR) status of tumor samples from the women. The study will recruit women 18 or older with ER positive metastatic breast cancer who have previously responded to adjuvant hormonal therapy for 3 years or longer and women diagnosed with metastatic disease who have been treated with hormonal therapy for at least 6 months and now have progressive disease.
About Breast Cancer And Receptor Status
Breast cancer is the most commonly diagnosed cancer in women, and the second leading cause of cancer deaths in women in the United States. Each year, over 200,000 new cases of invasive breast cancer will be diagnosed in the U.S., and approximately 39,000 women will die from the disease. Clinical assessment of breast cancer includes routine characterization of a patient’s receptor status, including the presence or absence of ER, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) in the tumor tissue. Receptor status is used to assess the potential for developing metastatic disease, as well as guiding treatment decisions. Hormonal manipulation with selective estrogen receptor modulators or aromatase inhibitors is the standard treatment given to patients with tumors that are ER positive. It is expected that a majority (70-95%) of women with ER positive breast cancer will also express AR in their primary tumor samples. High percentages (72-84%) of metastatic breast cancer lesions have also been found to be AR positive. In preclinical and clinical studies, androgens have been shown to suppress breast cancer growth. In addition, prior studies have shown that women with metastatic breast cancer who have been previously treated with tamoxifen and progress have responded to nonselective androgens like fluoxymesterone, medroxyprogesterone and danazol, with overall response rates ranging from 20 to 60%. Although these nonselective androgens have been used to treat breast cancer, the unwanted virilizing side effects, including facial and body hair, enlargement of voice box, acne, and edema, have limited their widespread clinical use.
About GTx
GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions.
SOURCE: GTx
Post Views: 243
MEMPHIS, TN, USA I April 30, 2013 I GTx, Inc. (GTXI), announced today that it is initiating a proof of concept, Phase 2, open-label clinical study to evaluate enobosarm (GTx-024), a selective androgen receptor modulator (SARM), for the potential treatment of metastatic breast cancer.
“We know from prior studies that women with hormone receptor positive metastatic breast cancer which has progressed following treatment with tamoxifen often respond to androgen (male hormone) therapy; yet the side effects, such as facial hair growth and deepening of the voice, are not acceptable to most patients,” said Beth A. Overmoyer, M.D., a clinical investigator in this enobosarm Phase 2 study and the Director, Inflammatory Breast Cancer Program, Dana Farber Cancer Institute and Assistant Professor of Medicine at the Harvard Medical School. “Hopefully, treatment with enobosarm will result in efficacy similar to androgen therapy without the masculinizing side effects.”
“We believe enobosarm has the potential to selectively treat metastatic breast cancer while minimizing the unwanted side effects associated with steroidal androgens,” said Mitchell S. Steiner, MD, Chief Executive Officer of GTx. “Enobosarm would be the first new targeted hormonal therapy introduced for the treatment of breast cancer in many years.”
The proof of concept, Phase 2, open-label study will randomize twenty (20) postmenopausal women with estrogen receptor (ER) positive metastatic breast cancer who have previously responded to hormone therapy at approximately six clinical sites in the United States. The women will receive 9 mg of enobosarm once a day until they evidence clinical progression or have completed 336 days of treatment. The primary endpoint is clinical benefit, which will be assessed at 6 months, and is defined as either those women receiving treatment who have demonstrated a complete response (disappearance of all targeted lesions), a partial response (at least a 30% decrease in the sum of the diameters of the targeted lesions) or stable disease (no disease progression from baseline). The response from treatment will be correlated with androgen receptor (AR) status of tumor samples from the women. The study will recruit women 18 or older with ER positive metastatic breast cancer who have previously responded to adjuvant hormonal therapy for 3 years or longer and women diagnosed with metastatic disease who have been treated with hormonal therapy for at least 6 months and now have progressive disease.
About Breast Cancer And Receptor Status
Breast cancer is the most commonly diagnosed cancer in women, and the second leading cause of cancer deaths in women in the United States. Each year, over 200,000 new cases of invasive breast cancer will be diagnosed in the U.S., and approximately 39,000 women will die from the disease. Clinical assessment of breast cancer includes routine characterization of a patient’s receptor status, including the presence or absence of ER, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) in the tumor tissue. Receptor status is used to assess the potential for developing metastatic disease, as well as guiding treatment decisions. Hormonal manipulation with selective estrogen receptor modulators or aromatase inhibitors is the standard treatment given to patients with tumors that are ER positive. It is expected that a majority (70-95%) of women with ER positive breast cancer will also express AR in their primary tumor samples. High percentages (72-84%) of metastatic breast cancer lesions have also been found to be AR positive. In preclinical and clinical studies, androgens have been shown to suppress breast cancer growth. In addition, prior studies have shown that women with metastatic breast cancer who have been previously treated with tamoxifen and progress have responded to nonselective androgens like fluoxymesterone, medroxyprogesterone and danazol, with overall response rates ranging from 20 to 60%. Although these nonselective androgens have been used to treat breast cancer, the unwanted virilizing side effects, including facial and body hair, enlargement of voice box, acne, and edema, have limited their widespread clinical use.
About GTx
GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions.
SOURCE: GTx
Post Views: 243
